Clinical Trial: Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance

U.S., Nov. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07933952) titled 'Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance' on Nov. 04.

Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis, and liver metastasis is a major contributor to treatment failure and reduced survival. Due to the complex mechanisms underlying tumor progression and metastasis, effective early diagnostic biomarkers and targeted therapeutic strategies remain limited. This study aims to investigate the molecular mechanisms underlying PDAC progression and liver metastasis, identify potential biomarkers for early risk prediction...